Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.190
-0.060 (-2.67%)
At close: Apr 28, 2026, 4:00 PM EDT
2.200
+0.010 (0.46%)
After-hours: Apr 28, 2026, 7:55 PM EDT
Allogene Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
152
Market Cap
753.31M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionALLO News
- 7 days ago - Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia - GlobeNewsWire
- 8 days ago - Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026 - GlobeNewsWire
- 12 days ago - Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock - GlobeNewsWire
- 13 days ago - Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases - GlobeNewsWire
- 14 days ago - Allogene Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 15 days ago - Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock - GlobeNewsWire
- 15 days ago - Allogene Therapeutics Transcript: Study result - Transcripts
- 15 days ago - Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma - Business Wire